<DOC>
	<DOCNO>NCT01688635</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics pharmacodynamics LY2963016 US-approved Lantus® . The study involve four single injection ; two dos LY2963016 two dose US-approved Lantus® . The study 4 period . In period , single injection administer undergoing euglycemic clamp last 24 hour . There least 7 day washout period . Side effect document . Study participation expect last 14 week .</brief_summary>
	<brief_title>A Study Compare LY2963016 US-approved Lantus® After Single Dose Administration Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Are overtly healthy male female Have body mass index 18.5 29.9 kilogram per meter square ( kg/m^2 ) Are nonsmoker smoke least 2 month prior enter study Have normal blood pressure pulse rate screen Have electrocardiogram ( ECGs ) screening consider within normal limit Have clinical laboratory test result within normal reference range Are currently enrol discontinue within last 30 day clinical study involve investigational drug device concurrently enrol type medical research Have know allergy insulin , excipients , related drug history relevant allergic reaction origin Have significant history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder Show evidence significant active neuropsychiatric disease , include take prescription medication diseases Show evidence current use know drug abuse history use within past year Have history firstdegree relative know diabetes mellitus Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody screen Have positive hepatitis B surface antigen screen Intend use overthecounter prescription medication within 7 14 day , respectively , prior dosing ( apart vitamin/mineral supplement , occasional paracetamol , thyroid replacement medication , birth control method ) Have donate blood loss 450 milliliter ( mL ) within 3 month prior study enrollment Have average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) unwilling stop alcohol consumption 24 hour prior dose discharge clinical research unit ( CRU )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Volunteers</keyword>
</DOC>